In sal­vage ef­fort, Sel­l­as cher­ry picks some pos­i­tive mid-stage can­cer vac­cine da­ta

Eight months af­ter Sel­l­as $SLS re­verse merged its way on­to Nas­daq through what was left of Gale­na fol­low­ing the piv­otal im­plo­sion of Neu­Vax, the mi­cro­cap biotech has cher­ry picked its way through some Phase IIb da­ta to high­light ev­i­dence of the can­cer vac­cine’s pos­si­ble po­ten­tial.

An­ge­los Ster­giou

Through a spokesper­son, Sel­l­as’ CEO An­ge­los Ster­giou re­fused to tell me what the p val­ue of the pri­ma­ry end­point in its study was, pre­fer­ring to high­light a clin­i­cal ben­e­fit for Neu­Vax in pro­long­ing dis­ease-free sur­vival when com­bined with Her­ceptin in treat­ing a group of breast can­cer pa­tients with triple-neg­a­tive breast can­cer. 

The biotech’s bad­ly bat­tered stock bounced 160% high­er on their re­lease.

Sel­l­as grabbed Gale­na af­ter the biotech’s shares were evis­cer­at­ed in June, 2016, drop­ping 78% af­ter the com­pa­ny an­nounced that it had stopped a Phase III study of its lead can­cer vac­cine af­ter the mon­i­tor­ing com­mit­tee flagged it for fail­ing to help breast can­cer vic­tims. Neu­Vax is part of a wave of can­cer vac­cines that flopped bad­ly in key stud­ies.

Ster­giou said in a state­ment that the biotech planned to ad­vance the can­cer vac­cine through a “part­ner­ship or oth­er strate­gic col­lab­o­ra­tion,” and he of­fered this quote about the re­sults via email:

It’s im­por­tant to keep in mind that this is an ex­plorato­ry tri­al in­tend­ed to find the right pop­u­la­tion to pur­sue in a de­fin­i­tive tri­al.  As such, we aren’t as sen­si­tive to al­pha spend which could cur­tail a de­fin­i­tive tri­al.  We do be­lieve that the curves will con­tin­ue to sep­a­rate as we be­lieve that the boost­er-main­tained im­muno­log­ic mem­o­ry helps pro­tect these pa­tients from late re­cur­rences. What is im­por­tant to note, and al­so stat­ed by the Da­ta Safe­ty Mon­i­tor­ing Board, is that we iden­ti­fied the TNBC pop­u­la­tion and, as per DSMB, it is not nec­es­sary to con­tin­ue the study due to the TNBC da­ta and to con­tin­ue fol­low­ing pa­tients for safe­ty but al­low­ing pa­tients to con­tin­ue their treat­ment.

The old Gale­na had been in and out of trou­ble ahead of the Sel­l­as takeover. Aside from the Neu­Vax set­back in 2016, the DoJ al­so stepped in to in­ves­ti­gate its pro­mo­tion­al prac­tices for the opi­oid Ab­stral. Back in 2011 the com­pa­ny changed its name from RXi to Gale­na, split­ting op­er­a­tions.

As for Sel­l­as, it once struck a high-pro­file li­cens­ing deal with Fo­s­un in 2013, but the deal col­lapsed with both sides ac­cus­ing the oth­er of fail­ing to make good. Fo­s­un said Sel­l­as nev­er de­liv­ered the cash it promised. Lat­er Sel­l­as moved from Zurich to New York to get in­to can­cer drug de­vel­op­ment.

Sel­l­as has a mar­ket cap of about $20 mil­lion. Its shares have steadi­ly lost val­ue over the years, at one point re­quir­ing a 1 for 20 re­verse split to get out of pen­ny stock ter­ri­to­ry.

Mi­no­ryx and Sper­o­genix ink an ex­clu­sive li­cense agree­ment to de­vel­op and com­mer­cial­ize lerigli­ta­zone in Chi­na

September 23, 2020 – Hong Kong, Beijing, Shanghai (China) and Mataró, Barcelona (Spain)  

Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales 

Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition

FDA chief Stephen Hahn on Capitol Hill earlier this week (Getty Images)

As FDA buck­les un­der the strain of a pan­dem­ic work­load, Trump again ac­cus­es the agency of a po­lit­i­cal hit job

Peter Marks appeared before a virtual SVB Leerink audience yesterday and said that his staff at FDA’s CBER is on the verge of working around the clock. Manufacturing inspections, policy work and sponsor communications have all been pushed down the to-do list so that they can be responsive to Covid-related interactions. And the agency’s objective right now? “To save as many lives as we can,” Marks said, likening the mortality on the current outbreak as equivalent to “a nuclear bomb on a small city.”

Daniel O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

Play-by-play of Gilead­'s $21B Im­munomedics buy­out de­tails a fren­zied push — and mints a new biotech bil­lion­aire

Immunomedics had not really been looking for a buyout when the year began. Excited by its BLA for Trodelvy, submitted to the FDA in late 2019, executive chairman Behzad Aghazadeh started off looking for potential licensing deals and zeroed in on four potential partners, including Gilead, following January’s JP Morgan Healthcare Conference in San Francisco. Such talks advanced throughout the year, with discussions advancing to the second round in mid-August.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

The win­dow is wide open as four more biotechs join the go-go IPO class of 2020

It’s another day of hauling cash in the biopharma world as four more IPOs priced Friday and a fifth filed its initial paperwork.

The biggest offering comes from PMV Pharma, an oncology biotech focusing on p53 mutations, which raised $211.8 million after pricing shares at $18 apiece. Prelude Therapeutics, developing PRMT5 inhibitors for rare cancers, was next with a $158 million raise, pricing shares at $19 each. Graybug Vision raised $90 million after pricing at $16 per share for its wet AMD candidates, and breast cancer biotech Greenwich Lifesciences brought up the rear with a small, $7 million raise after pricing shares at $5.75.

J&J of­fers PhI/IIa da­ta show­ing its sin­gle-dose vac­cine can stir up suf­fi­cient im­mune re­sponse

Days after J&J dosed the first participants of its Phase III ENSEMBLE trial, the pharma giant has detailed the early-stage data that gave them confidence in a single-dose regimen.

Testing two dose levels either as a single dose or in a two-dose schedule spaced by 56 days in, the scientists from Janssen, the J&J subsidiary developing its vaccine, reported that the low dose induced a similar immune response as the high dose. The interim Phase I/IIa results were posted in a preprint on medRxiv.

President Donald Trump reacts after signing an executive order following his remarks on his healthcare policies yesterday in Charlotte, North Carolina (Getty Images)

Op-ed: Will phar­ma re­al­ly pay for Trump’s lat­est law­less promise to 33 mil­lion Medicare ben­e­fi­cia­ries? Not like­ly

Sitting atop the executive branch, President Donald Trump is the ultimate authority at the FDA. He can fast track any vaccine to approval himself. If it came to that, of course.

What he can’t do is unilaterally order the legislative branch to loosen the Treasury’s coffers for $6.6 billion. Nor can he command pharmaceutical companies to pay for $200 vouchers sent to 33 million Medicare beneficiaries for prescription drugs before the election.

Pal­la­dio bags $20 mil­lion Se­ries B to top­ple a prob­lem­at­ic kid­ney dis­ease drug

Palladio Biosciences just took one step further in its quest to topple Otsuka’s Samsca with its own — it hopes safer — autosomal dominant polycystic kidney disease (ADPKD) drug.

The Pennsylvania-based biotech announced a $20 million Series B on Friday, which will fund a 10-person Phase III trial of its vasopressin V2 receptor agonist, lixivaptan. CEO Alex Martin expects to read out data in the first half of next year, then launch straight into a larger pivotal Phase III study with about 1,200 participants.

New York governor Andrew Cuomo (AP Images)

An­drew Cuo­mo says New York will un­der­take its own vac­cine re­view process, and wouldn’t rec­om­mend trust­ing the fed­er­al gov­ern­ment

The concerns keep mounting over President Donald Trump’s politicization of the FDA and other federal agencies guiding the development of a safe and effective vaccine. And today, the telegenic New York governor Andrew Cuomo appeared to introduce even more politics into the matter — latest in an ongoing series of incidents that have cast the proudly independent FDA in starkly political terms.

During his daily press conference Cuomo said that the state will review any coronavirus vaccines approved by the federal government, citing a lack of trust in the Trump administration. The announcement comes one day after Trump accused the FDA of making an “extremely political” move in proposing stricter vaccine guidance.

PhII Alzheimer's fail­ure deals new blow to Roche, AC Im­mune — but the tau hy­poth­e­sis is far from dead

The leading anti-tau antibody has failed its first Phase II testing, casting a shadow on a popular target (just trailing amyloid beta) for Alzheimer’s disease.

Roche and AC Immune are quick to acknowledge disappointment in the topline readout, which suggested that semorinemab did not reduce cognitive decline among patients with early Alzheimer’s disease, who are either just starting to have symptoms or have mild manifestations.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.